ID   FIBB_HUMAN              Reviewed;         491 AA.
AC   P02675; A0JLR9; B2R7G3; Q32Q65; Q3KPF2;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1993, sequence version 2.
DT   28-JAN-2026, entry version 261.
DE   RecName: Full=Fibrinogen beta chain;
DE   Contains:
DE     RecName: Full=Fibrinopeptide B;
DE   Contains:
DE     RecName: Full=Fibrinogen beta chain;
DE   Flags: Precursor;
GN   Name=FGB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RX   PubMed=6688356; DOI=10.1021/bi00282a032;
RA   Chung D.W., Que B.G., Rixon M.W., Mace M. Jr., Davie E.W.;
RT   "Characterization of complementary deoxyribonucleic acid and genomic
RT   deoxyribonucleic acid for the beta chain of human fibrinogen.";
RL   Biochemistry 22:3244-3250(1983).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2102623; DOI=10.1007/978-1-4615-3806-6_3;
RA   Chung D.W., Harris J.E., Davie E.W.;
RT   "Nucleotide sequences of the three genes coding for human fibrinogen.";
RL   Adv. Exp. Med. Biol. 281:39-48(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Chung D.W., Harris J.E., Davie E.W.;
RT   "Nucleotide sequences of the three genes coding for human fibrinogen.";
RL   (In) Liu C.Y., Chien S. (eds.);
RL   Fibrinogen, thrombosis, coagulation and fibrinolysis, pp.39-48, Plenum
RL   Press, New York (1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-100; HIS-170; LEU-265
RP   AND LYS-478.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Mammary gland;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-60.
RX   PubMed=6575700; DOI=10.1111/j.1749-6632.1983.tb23265.x;
RA   Chung D.W., Rixon M.W., Que B.G., Davie E.W.;
RT   "Cloning of fibrinogen genes and their cDNA.";
RL   Ann. N. Y. Acad. Sci. 408:449-456(1983).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-38.
RX   PubMed=3029722; DOI=10.1093/nar/15.4.1615;
RA   Huber P., Dalmon J., Courtois G., Laurent M., Assouline Z., Marguerie G.;
RT   "Characterization of the 5'-flanking region for the human fibrinogen beta
RT   gene.";
RL   Nucleic Acids Res. 15:1615-1625(1987).
RN   [10]
RP   PROTEIN SEQUENCE OF 31-491, AND PYROGLUTAMATE FORMATION AT GLN-31.
RX   PubMed=420779; DOI=10.1021/bi00568a011;
RA   Watt K.W.K., Takagi T., Doolittle R.F.;
RT   "Amino acid sequence of the beta chain of human fibrinogen.";
RL   Biochemistry 18:68-76(1979).
RN   [11]
RP   PROTEIN SEQUENCE OF 31-491, AND GLYCOSYLATION AT ASN-394.
RA   Henschen A., Lottspeich F., Southan C., Topfer-Petersen E.;
RT   "Human fibrinogen: sequence, sulfur bridges, glycosylation and some
RT   structural variants.";
RL   (In) Peeters H. (eds.);
RL   Protides of the biological fluids, Proc. 28th colloquium, pp.51-56,
RL   Pergamon Press, Oxford (1980).
RN   [12]
RP   PROTEIN SEQUENCE OF 31-148, AND DISULFIDE BONDS.
RX   PubMed=936108; DOI=10.1016/0049-3848(76)90245-0;
RA   Blombaeck B., Hessel B., Hogg D.;
RT   "Disulfide bridges in NH2-terminal part of human fibrinogen.";
RL   Thromb. Res. 8:639-658(1976).
RN   [13]
RP   PROTEIN SEQUENCE OF 31-44.
RA   Blombaeck B., Blombaeck M., Grondahl N.J., Guthrie C., Hinton M.;
RT   "Studies on fibrinopeptides from primates.";
RL   Acta Chem. Scand. 19:1788-1789(1965).
RN   [14]
RP   PROTEIN SEQUENCE OF 45-53.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R.,
RA   Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass spectrometric
RT   identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [15]
RP   PROTEIN SEQUENCE OF 54-72; 164-178 AND 225-239, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Fetal brain cortex;
RA   Lubec G., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [16]
RP   REVIEW, AND DISULFIDE BONDS.
RX   PubMed=6575689; DOI=10.1111/j.1749-6632.1983.tb23232.x;
RA   Henschen A., Lottspeich F., Kehl M., Southan C.;
RT   "Covalent structure of fibrinogen.";
RL   Ann. N. Y. Acad. Sci. 408:28-43(1983).
RN   [17]
RP   DISULFIDE BONDS.
RX   PubMed=891553; DOI=10.1111/j.1432-1033.1977.tb11704.x;
RA   Gaardlund B., Hessel B., Marguerie G., Murano G., Blombaeck B.;
RT   "Primary structure of human fibrinogen. Characterization of disulfide-
RT   containing cyanogen-bromide fragments.";
RL   Eur. J. Biochem. 77:595-610(1977).
RN   [18]
RP   DISULFIDE BONDS.
RA   Doolittle R.F., Takagi T., Watt K.W.K., Bouma H. III, Cottrell B.A.,
RA   Cassman K.G., Goldbaum D.M., Doolittle L.R., Friezner S.J.;
RT   "The structures of fibrinogen and fibrin.";
RL   (In) Magnusson S., Ottesen M., Foltmann B., Dano K., Neurath H. (eds.);
RL   Regulatory proteolytic enzymes and their inhibitors, pp.163-172, Pergamon
RL   Press, New York (1978).
RN   [19]
RP   REVIEW, ELECTRON MICROSCOPY, POLYMERIZATION, AND LIGANDS.
RX   PubMed=6383194; DOI=10.1146/annurev.bi.53.070184.001211;
RA   Doolittle R.F.;
RT   "Fibrinogen and fibrin.";
RL   Annu. Rev. Biochem. 53:195-229(1984).
RN   [20]
RP   INTERACTION WITH FBLN1.
RX   PubMed=7642629; DOI=10.1074/jbc.270.33.19458;
RA   Tran H., Tanaka A., Litvinovich S.V., Medved L.V., Haudenschild C.C.,
RA   Argraves W.S.;
RT   "The interaction of fibulin-1 with fibrinogen. A potential role in
RT   hemostasis and thrombosis.";
RL   J. Biol. Chem. 270:19458-19464(1995).
RN   [21]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-394.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J.,
RA   Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [22]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-394.
RC   TISSUE=Platelet;
RX   PubMed=16263699; DOI=10.1074/mcp.m500324-mcp200;
RA   Lewandrowski U., Moebius J., Walter U., Sickmann A.;
RT   "Elucidation of N-glycosylation sites on human platelet proteins: a
RT   glycoproteomic approach.";
RL   Mol. Cell. Proteomics 5:226-233(2006).
RN   [23]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-394.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [24]
RP   CLEAVAGE BY HEMENTIN AND PLASMIN.
RX   PubMed=2143188; DOI=10.1016/s0021-9258(18)77401-2;
RA   Kirschbaum N.E., Budzynski A.Z.;
RT   "A unique proteolytic fragment of human fibrinogen containing the A alpha
RT   COOH-terminal domain of the native molecule.";
RL   J. Biol. Chem. 265:13669-13676(1990).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 164-491, DISULFIDE BONDS, AND
RP   SUBUNIT.
RX   PubMed=9333233; DOI=10.1038/38947;
RA   Spraggon G., Everse S.J., Doolittle R.F.;
RT   "Crystal structures of fragment D from human fibrinogen and its crosslinked
RT   counterpart from fibrin.";
RL   Nature 389:455-462(1997).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 164-491 IN COMPLEX WITH CALCIUM,
RP   DISULFIDE BONDS, GLYCOSYLATION AT ASN-394, SUBUNIT, COILED COIL DOMAIN,
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=9628725; DOI=10.1021/bi9804129;
RA   Everse S.J., Spraggon G., Veerapandian L., Riley M., Doolittle R.F.;
RT   "Crystal structure of fragment double-D from human fibrin with two
RT   different bound ligands.";
RL   Biochemistry 37:8637-8642(1998).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 164-491 IN COMPLEX WITH CALCIUM,
RP   DISULFIDE BONDS, GLYCOSYLATION AT ASN-394, SUBUNIT, SUBCELLULAR LOCATION,
RP   TISSUE SPECIFICITY, AND COILED COIL DOMAIN.
RX   PubMed=10074346; DOI=10.1021/bi982626w;
RA   Everse S.J., Spraggon G., Veerapandian L., Doolittle R.F.;
RT   "Conformational changes in fragments D and double-D from human fibrin(ogen)
RT   upon binding the peptide ligand Gly-His-Arg-Pro-amide.";
RL   Biochemistry 38:2941-2946(1999).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 31-491 IN COMPLEX WITH CALCIUM,
RP   DISULFIDE BONDS, GLYCOSYLATION AT ASN-394, SUBUNIT, SUBCELLULAR LOCATION,
RP   TISSUE SPECIFICITY, AND COILED COIL DOMAIN.
RX   PubMed=19296670; DOI=10.1021/bi802205g;
RA   Kollman J.M., Pandi L., Sawaya M.R., Riley M., Doolittle R.F.;
RT   "Crystal structure of human fibrinogen.";
RL   Biochemistry 48:3877-3886(2009).
RN   [31]
RP   VARIANT LYS-478.
RX   PubMed=3194892; DOI=10.1016/0049-3848(88)90096-5;
RA   Schmelzer C.H., Ebert R.F., Bell W.R.;
RT   "A polymorphism at B beta 448 of fibrinogen identified during structural
RT   studies of fibrinogen Baltimore II.";
RL   Thromb. Res. 52:173-177(1988).
RN   [32]
RP   VARIANT ARG-45.
RX   PubMed=2018836;
RA   Yoshida N., Wada H., Morita K., Hirata H., Matsuda M., Yamazumi K.,
RA   Asakura S., Shirakawa S.;
RT   "A new congenital abnormal fibrinogen Ise characterized by the replacement
RT   of B beta glycine-15 by cysteine.";
RL   Blood 77:1958-1963(1991).
RN   [33]
RP   INVOLVEMENT IN DYSFIBRIN, AND VARIANT DYSFIBRIN THR-98.
RX   PubMed=1634610; DOI=10.1172/jci115841;
RA   Koopman J., Haverkate F., Lord S.T., Grimbergen J., Mannucci P.M.;
RT   "Molecular basis of fibrinogen Naples associated with defective thrombin
RT   binding and thrombophilia. Homozygous substitution of B beta 68
RT   Ala-->Thr.";
RL   J. Clin. Invest. 90:238-244(1992).
RN   [34]
RP   VARIANTS CYS-44 AND CYS-74.
RX   PubMed=1565641; DOI=10.1073/pnas.89.8.3478;
RA   Koopman J., Haverkate F., Grimbergen J., Engesser L., Novakova I.,
RA   Kerst A.F.J.A., Lord S.T.;
RT   "Abnormal fibrinogens IJmuiden (B beta Arg14-->Cys) and Nijmegen (B beta
RT   Arg44-->Cys) form disulfide-linked fibrinogen-albumin complexes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:3478-3482(1992).
RN   [35]
RP   VARIANT 39-GLY--LEU-102 DEL.
RX   PubMed=3156856; DOI=10.1016/s0021-9258(18)89277-8;
RA   Liu C.Y., Koehn J.A., Morgan F.J.;
RT   "Characterization of fibrinogen New York 1. A dysfunctional fibrinogen with
RT   a deletion of B beta(9-72) corresponding exactly to exon 2 of the gene.";
RL   J. Biol. Chem. 260:4390-4396(1985).
RN   [36]
RP   VARIANTS GLU-2; LEU-265 AND LYS-478.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions of
RT   human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [37]
RP   ERRATUM OF PUBMED:10391209.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [38]
RP   VARIANTS CAFBN ARG-383 AND ASP-430.
RX   PubMed=10666208;
RA   Duga S., Asselta R., Santagostino E., Zeinali S., Simonic T., Malcovati M.,
RA   Mannucci P.M., Tenchini M.L.;
RT   "Missense mutations in the human beta fibrinogen gene cause congenital
RT   afibrinogenemia by impairing fibrinogen secretion.";
RL   Blood 95:1336-1341(2000).
RN   [39]
RP   VARIANT CAFBN CYS-196.
RX   PubMed=11468164; DOI=10.1182/blood.v98.3.661;
RA   Lounes K.C., Lefkowitz J.B., Henschen-Edman A.H., Coates A.I.,
RA   Hantgan R.R., Lord S.T.;
RT   "The impaired polymerization of fibrinogen Longmont (Bbeta166Arg-->Cys) is
RT   not improved by removal of disulfide-linked dimers from a mixture of dimers
RT   and cysteine-linked monomers.";
RL   Blood 98:661-666(2001).
RN   [40]
RP   VARIANT CAFBN GLN-202.
RX   PubMed=15070683; DOI=10.1182/blood-2003-10-3725;
RA   Asselta R., Duga S., Spena S., Peyvandi F., Castaman G., Malcovati M.,
RA   Mannucci P.M., Tenchini M.L.;
RT   "Missense or splicing mutation? The case of a fibrinogen Bbeta-chain
RT   mutation causing severe hypofibrinogenemia.";
RL   Blood 103:3051-3054(2004).
RN   [41]
RP   VARIANTS CAFBN ARG-95 AND LYS-407, AND CHARACTERIZATION OF VARIANTS CAFBN
RP   ARG-95 AND LYS-407.
RX   PubMed=25427968; DOI=10.1160/th14-07-0629;
RA   Asselta R., Plate M., Robusto M., Borhany M., Guella I., Solda G.,
RA   Afrasiabi A., Menegatti M., Shamsi T., Peyvandi F., Duga S.;
RT   "Clinical and molecular characterisation of 21 patients affected by
RT   quantitative fibrinogen deficiency.";
RL   Thromb. Haemost. 113:567-576(2015).
CC   -!- FUNCTION: Cleaved by the protease thrombin to yield monomers which,
CC       together with fibrinogen alpha (FGA) and fibrinogen gamma (FGG),
CC       polymerize to form an insoluble fibrin matrix. Fibrin has a major
CC       function in hemostasis as one of the primary components of blood clots.
CC       In addition, functions during the early stages of wound repair to
CC       stabilize the lesion and guide cell migration during re-
CC       epithelialization. Was originally thought to be essential for platelet
CC       aggregation, based on in vitro studies using anticoagulated blood.
CC       However subsequent studies have shown that it is not absolutely
CC       required for thrombus formation in vivo. Enhances expression of SELP in
CC       activated platelets. Maternal fibrinogen is essential for successful
CC       pregnancy. Fibrin deposition is also associated with infection, where
CC       it protects against IFNG-mediated hemorrhage. May also facilitate the
CC       antibacterial immune response via both innate and T-cell mediated
CC       pathways. {ECO:0000250|UniProtKB:E9PV24}.
CC   -!- SUBUNIT: Heterohexamer; disulfide linked. Contains 2 sets of 3 non-
CC       identical chains (alpha, beta and gamma). The 2 heterotrimers are in
CC       head to head conformation with the N-termini in a small central domain.
CC       {ECO:0000269|PubMed:10074346, ECO:0000269|PubMed:19296670,
CC       ECO:0000269|PubMed:9333233, ECO:0000269|PubMed:9628725}.
CC   -!- INTERACTION:
CC       P02675; PRO_0000037566 [P27958]; Xeno; NbExp=4; IntAct=EBI-1034445, EBI-6377335;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:10074346,
CC       ECO:0000269|PubMed:19296670, ECO:0000269|PubMed:9628725}.
CC   -!- TISSUE SPECIFICITY: Detected in blood plasma (at protein level).
CC       {ECO:0000269|PubMed:10074346, ECO:0000269|PubMed:19296670,
CC       ECO:0000269|PubMed:9628725}.
CC   -!- DOMAIN: A long coiled coil structure formed by 3 polypeptide chains
CC       connects the central nodule to the C-terminal domains (distal nodules).
CC       The long C-terminal ends of the alpha chains fold back, contributing a
CC       fourth strand to the coiled coil structure.
CC       {ECO:0000269|PubMed:10074346, ECO:0000269|PubMed:19296670,
CC       ECO:0000269|PubMed:9628725}.
CC   -!- PTM: Conversion of fibrinogen to fibrin is triggered by thrombin, which
CC       cleaves fibrinopeptides A and B from alpha and beta chains, and thus
CC       exposes the N-terminal polymerization sites responsible for the
CC       formation of the soft clot. The soft clot is converted into the hard
CC       clot by factor XIIIA which catalyzes the epsilon-(gamma-glutamyl)lysine
CC       cross-linking between gamma chains (stronger) and between alpha chains
CC       (weaker) of different monomers. {ECO:0000269|PubMed:2143188}.
CC   -!- DISEASE: Congenital afibrinogenemia (CAFBN) [MIM:202400]: Rare
CC       autosomal recessive disorder is characterized by bleeding that varies
CC       from mild to severe and by complete absence or extremely low levels of
CC       plasma and platelet fibrinogen. {ECO:0000269|PubMed:10666208,
CC       ECO:0000269|PubMed:11468164, ECO:0000269|PubMed:15070683,
CC       ECO:0000269|PubMed:25427968}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry. Patients with congenital
CC       fibrinogen abnormalities can manifest different clinical pictures. Some
CC       cases are clinically silent, some show a tendency toward bleeding and
CC       some show a predisposition for thrombosis with or without bleeding.
CC   -!- DISEASE: Dysfibrinogenemia, congenital (DYSFIBRIN) [MIM:616004]: A
CC       disorder characterized by qualitative abnormalities (dysfibrinogenemia)
CC       of the circulating fibrinogen. Affected individuals are frequently
CC       asymptomatic, but some patients have bleeding diathesis, thromboembolic
CC       complications, or both. In some cases, dysfibrinogenemia is associated
CC       with low circulating fibrinogen levels (hypodysfibrinogenemia).
CC       {ECO:0000269|PubMed:1634610}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH07030.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Fibrinogen entry;
CC       URL="https://en.wikipedia.org/wiki/Fibrinogen";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; J00129; AAA52429.1; -; mRNA.
DR   EMBL; J00131; AAA98115.1; -; Genomic_DNA.
DR   EMBL; J00130; AAA98115.1; JOINED; Genomic_DNA.
DR   EMBL; J00132; AAA98116.1; -; Genomic_DNA.
DR   EMBL; J00133; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; M64983; AAA18024.2; -; Genomic_DNA.
DR   EMBL; AF388026; AAK62470.1; -; Genomic_DNA.
DR   EMBL; AK312972; BAG35810.1; -; mRNA.
DR   EMBL; CH471056; EAX04932.1; -; Genomic_DNA.
DR   EMBL; BC007030; AAH07030.1; ALT_SEQ; mRNA.
DR   EMBL; BC106760; AAI06761.1; -; mRNA.
DR   EMBL; BC107766; AAI07767.1; -; mRNA.
DR   EMBL; AH002694; AAA52445.1; -; Genomic_DNA.
DR   EMBL; X05018; CAA28674.1; -; Genomic_DNA.
DR   CCDS; CCDS3786.1; -.
DR   PIR; B43568; FGHUB.
DR   RefSeq; NP_001171670.1; NM_001184741.1.
DR   RefSeq; NP_005132.2; NM_005141.5.
DR   PDB; 1FZA; X-ray; 2.90 A; B/E=164-491.
DR   PDB; 1FZB; X-ray; 2.90 A; B/E=164-491.
DR   PDB; 1FZC; X-ray; 2.30 A; B/E=164-491.
DR   PDB; 1FZE; X-ray; 3.00 A; B/E=164-491.
DR   PDB; 1FZF; X-ray; 2.70 A; B/E=164-491, M/N/S/T=45-48.
DR   PDB; 1FZG; X-ray; 2.50 A; B/E=164-491.
DR   PDB; 1LT9; X-ray; 2.80 A; B/E=179-491.
DR   PDB; 1LTJ; X-ray; 2.80 A; B/E=179-491.
DR   PDB; 1N86; X-ray; 3.20 A; B/E=164-491, I/J=45-51.
DR   PDB; 1N8E; X-ray; 4.50 A; B/E=164-491.
DR   PDB; 1RE3; X-ray; 2.45 A; B/E=179-491.
DR   PDB; 1RE4; X-ray; 2.70 A; B/E=179-491.
DR   PDB; 1RF0; X-ray; 2.81 A; B/E=179-491.
DR   PDB; 1RF1; X-ray; 2.53 A; B/E=179-491.
DR   PDB; 2A45; X-ray; 3.65 A; H/K=45-135.
DR   PDB; 2FFD; X-ray; 2.89 A; B/E=179-491.
DR   PDB; 2H43; X-ray; 2.70 A; B/E=164-491.
DR   PDB; 2HLO; X-ray; 2.60 A; B/E=164-491.
DR   PDB; 2HOD; X-ray; 2.90 A; B/E/H/K=164-491.
DR   PDB; 2HPC; X-ray; 2.90 A; B/E/H/K=164-491.
DR   PDB; 2OYH; X-ray; 2.40 A; B/E=179-491.
DR   PDB; 2OYI; X-ray; 2.70 A; B/E=179-491.
DR   PDB; 2Q9I; X-ray; 2.80 A; B/E=164-491.
DR   PDB; 2XNX; X-ray; 3.30 A; B/E/H/K=164-491.
DR   PDB; 2XNY; X-ray; 7.50 A; B/E=164-491.
DR   PDB; 2Z4E; X-ray; 2.70 A; B/E=164-489.
DR   PDB; 3BVH; X-ray; 2.60 A; B/E=191-488.
DR   PDB; 3E1I; X-ray; 2.30 A; B/E=164-491.
DR   PDB; 3GHG; X-ray; 2.90 A; B/E/H/K=31-491.
DR   PDB; 3H32; X-ray; 3.60 A; B/E=31-488.
DR   PDB; 3HUS; X-ray; 3.04 A; B/E=179-491.
DR   PDB; 6ATZ; X-ray; 2.70 A; E/F=69-79.
DR   PDB; 6BIJ; X-ray; 2.10 A; C=69-81.
DR   PDB; 6BIL; X-ray; 2.40 A; C=69-81.
DR   PDB; 6V0Y; X-ray; 2.70 A; C=69-81.
DR   PDB; 6V13; X-ray; 2.75 A; C=69-81.
DR   PDB; 6V15; X-ray; 2.80 A; C=69-81.
DR   PDB; 6V18; X-ray; 2.35 A; C=69-81.
DR   PDB; 6V19; X-ray; 2.60 A; C=69-81.
DR   PDB; 6V1A; X-ray; 2.29 A; C=69-81.
DR   PDBsum; 1FZA; -.
DR   PDBsum; 1FZB; -.
DR   PDBsum; 1FZC; -.
DR   PDBsum; 1FZE; -.
DR   PDBsum; 1FZF; -.
DR   PDBsum; 1FZG; -.
DR   PDBsum; 1LT9; -.
DR   PDBsum; 1LTJ; -.
DR   PDBsum; 1N86; -.
DR   PDBsum; 1N8E; -.
DR   PDBsum; 1RE3; -.
DR   PDBsum; 1RE4; -.
DR   PDBsum; 1RF0; -.
DR   PDBsum; 1RF1; -.
DR   PDBsum; 2A45; -.
DR   PDBsum; 2FFD; -.
DR   PDBsum; 2H43; -.
DR   PDBsum; 2HLO; -.
DR   PDBsum; 2HOD; -.
DR   PDBsum; 2HPC; -.
DR   PDBsum; 2OYH; -.
DR   PDBsum; 2OYI; -.
DR   PDBsum; 2Q9I; -.
DR   PDBsum; 2XNX; -.
DR   PDBsum; 2XNY; -.
DR   PDBsum; 2Z4E; -.
DR   PDBsum; 3BVH; -.
DR   PDBsum; 3E1I; -.
DR   PDBsum; 3GHG; -.
DR   PDBsum; 3H32; -.
DR   PDBsum; 3HUS; -.
DR   PDBsum; 6ATZ; -.
DR   PDBsum; 6BIJ; -.
DR   PDBsum; 6BIL; -.
DR   PDBsum; 6V0Y; -.
DR   PDBsum; 6V13; -.
DR   PDBsum; 6V15; -.
DR   PDBsum; 6V18; -.
DR   PDBsum; 6V19; -.
DR   PDBsum; 6V1A; -.
DR   AlphaFoldDB; P02675; -.
DR   SMR; P02675; -.
DR   BioGRID; 108535; 243.
DR   ComplexPortal; CPX-1922; Fibrinogen complex.
DR   ComplexPortal; CPX-6225; Fibrin complex.
DR   CORUM; P02675; -.
DR   DIP; DIP-385N; -.
DR   FunCoup; P02675; 400.
DR   IntAct; P02675; 168.
DR   MINT; P02675; -.
DR   STRING; 9606.ENSP00000306099; -.
DR   BindingDB; P02675; -.
DR   ChEMBL; CHEMBL2048; -.
DR   DrugBank; DB04919; Alfimeprase.
DR   DrugBank; DB13151; Anti-inhibitor coagulant complex.
DR   DrugBank; DB11571; Human thrombin.
DR   DrugBank; DB11311; Prothrombin.
DR   DrugBank; DB00364; Sucralfate.
DR   DrugBank; DB11300; Thrombin.
DR   DrugBank; DB11572; Thrombin alfa.
DR   UniLectin; P02675; -.
DR   CarbonylDB; P02675; -.
DR   GlyConnect; 157; 4 N-Linked glycans.
DR   GlyConnect; 159; 31 N-Linked glycans (1 site).
DR   GlyCosmos; P02675; 3 sites, 33 glycans.
DR   GlyGen; P02675; 9 sites, 119 N-linked glycans (2 sites), 5 O-linked glycans (6 sites).
DR   iPTMnet; P02675; -.
DR   PhosphoSitePlus; P02675; -.
DR   SwissPalm; P02675; -.
DR   BioMuta; FGB; -.
DR   DMDM; 399492; -.
DR   OGP; P02675; -.
DR   REPRODUCTION-2DPAGE; IPI00298497; -.
DR   REPRODUCTION-2DPAGE; P02675; -.
DR   CPTAC; non-CPTAC-1119; -.
DR   CPTAC; non-CPTAC-1120; -.
DR   CPTAC; non-CPTAC-2665; -.
DR   jPOST; P02675; -.
DR   MassIVE; P02675; -.
DR   PaxDb; 9606-ENSP00000306099; -.
DR   PeptideAtlas; P02675; -.
DR   PRIDE; P02675; -.
DR   ProteomicsDB; 51544; -.
DR   Pumba; P02675; -.
DR   ABCD; P02675; 8 sequenced antibodies.
DR   Antibodypedia; 855; 619 antibodies from 38 providers.
DR   DNASU; 2244; -.
DR   Ensembl; ENST00000302068.9; ENSP00000306099.4; ENSG00000171564.13.
DR   GeneID; 2244; -.
DR   KEGG; hsa:2244; -.
DR   MANE-Select; ENST00000302068.9; ENSP00000306099.4; NM_005141.5; NP_005132.2.
DR   AGR; HGNC:3662; -.
DR   ClinPGx; PA163; -.
DR   CTD; 2244; -.
DR   DisGeNET; 2244; -.
DR   GeneCards; FGB; -.
DR   HGNC; HGNC:3662; FGB.
DR   HPA; ENSG00000171564; Tissue enriched (liver).
DR   MalaCards; FGB; -.
DR   MIM; 134830; gene.
DR   MIM; 202400; phenotype.
DR   MIM; 616004; phenotype.
DR   OpenTargets; ENSG00000171564; -.
DR   Orphanet; 98880; Familial afibrinogenemia.
DR   Orphanet; 98881; Familial dysfibrinogenemia.
DR   Orphanet; 248408; Familial hypodysfibrinogenemia.
DR   Orphanet; 101041; Familial hypofibrinogenemia.
DR   VEuPathDB; HostDB:ENSG00000171564; -.
DR   eggNOG; KOG2579; Eukaryota.
DR   GeneTree; ENSGT00940000158122; -.
DR   HOGENOM; CLU_038628_13_0_1; -.
DR   InParanoid; P02675; -.
DR   OMA; GCIHADP; -.
DR   OrthoDB; 9930906at2759; -.
DR   PAN-GO; P02675; 5 GO annotations based on evolutionary models.
DR   PhylomeDB; P02675; -.
DR   BioCyc; MetaCyc:ENSG00000171564-MONOMER; -.
DR   PathwayCommons; P02675; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-1236974; ER-Phagosome pathway.
DR   Reactome; R-HSA-140875; Common Pathway of Fibrin Clot Formation.
DR   Reactome; R-HSA-166058; MyD88:MAL(TIRAP) cascade initiated on plasma membrane.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-354192; Integrin signaling.
DR   Reactome; R-HSA-354194; GRB2:SOS provides linkage to MAPK signaling for Integrins.
DR   Reactome; R-HSA-372708; p130Cas linkage to MAPK signaling for integrins.
DR   Reactome; R-HSA-5602498; MyD88 deficiency (TLR2/4).
DR   Reactome; R-HSA-5603041; IRAK4 deficiency (TLR2/4).
DR   Reactome; R-HSA-5674135; MAP2K and MAPK activation.
DR   Reactome; R-HSA-5686938; Regulation of TLR by endogenous ligand.
DR   Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions.
DR   Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF.
DR   Reactome; R-HSA-9649948; Signaling downstream of RAS mutants.
DR   Reactome; R-HSA-9656223; Signaling by RAF1 mutants.
DR   SignaLink; P02675; -.
DR   SIGNOR; P02675; -.
DR   Agora; ENSG00000171564; -.
DR   BioGRID-ORCS; 2244; 15 hits in 1148 CRISPR screens.
DR   CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities.
DR   ChiTaRS; FGB; human.
DR   EvolutionaryTrace; P02675; -.
DR   GeneWiki; Fibrinogen_beta_chain; -.
DR   GenomeRNAi; 2244; -.
DR   Pharos; P02675; Tbio.
DR   PRO; PR:P02675; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; P02675; protein.
DR   Bgee; ENSG00000171564; Expressed in right lobe of liver and 119 other cell types or tissues.
DR   ExpressionAtlas; P02675; baseline and differential.
DR   GO; GO:0072562; C:blood microparticle; HDA:UniProtKB.
DR   GO; GO:0005938; C:cell cortex; IEA:Ensembl.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; HDA:BHF-UCL.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:1903561; C:extracellular vesicle; HDA:UniProtKB.
DR   GO; GO:0005577; C:fibrinogen complex; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0031091; C:platelet alpha granule; IDA:BHF-UCL.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0045202; C:synapse; IEA:Ensembl.
DR   GO; GO:0005201; F:extracellular matrix structural constituent; HDA:BHF-UCL.
DR   GO; GO:0051087; F:protein-folding chaperone binding; IPI:BHF-UCL.
DR   GO; GO:0005102; F:signaling receptor binding; IEA:InterPro.
DR   GO; GO:0005198; F:structural molecule activity; IDA:BHF-UCL.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0072378; P:blood coagulation, fibrin clot formation; IDA:UniProtKB.
DR   GO; GO:0007160; P:cell-matrix adhesion; IDA:BHF-UCL.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IEA:Ensembl.
DR   GO; GO:0044320; P:cellular response to leptin stimulus; IEA:Ensembl.
DR   GO; GO:0042730; P:fibrinolysis; IDA:UniProtKB.
DR   GO; GO:0043152; P:induction of bacterial agglutination; IDA:CACAO.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IDA:BHF-UCL.
DR   GO; GO:1902042; P:negative regulation of extrinsic apoptotic signaling pathway via death domain receptors; IDA:BHF-UCL.
DR   GO; GO:0031639; P:plasminogen activation; IDA:UniProtKB.
DR   GO; GO:0070527; P:platelet aggregation; IDA:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:BHF-UCL.
DR   GO; GO:0045921; P:positive regulation of exocytosis; IDA:BHF-UCL.
DR   GO; GO:0034116; P:positive regulation of heterotypic cell-cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0090277; P:positive regulation of peptide hormone secretion; IDA:BHF-UCL.
DR   GO; GO:0050714; P:positive regulation of protein secretion; IDA:BHF-UCL.
DR   GO; GO:1900026; P:positive regulation of substrate adhesion-dependent cell spreading; NAS:BHF-UCL.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IDA:BHF-UCL.
DR   GO; GO:0051258; P:protein polymerization; IDA:BHF-UCL.
DR   GO; GO:0065003; P:protein-containing complex assembly; IDA:BHF-UCL.
DR   GO; GO:0051592; P:response to calcium ion; IDA:BHF-UCL.
DR   CDD; cd00087; FReD; 1.
DR   FunFam; 1.20.5.50:FF:000004; Fibrinogen beta chain; 1.
DR   FunFam; 3.90.215.10:FF:000006; Fibrinogen beta chain; 1.
DR   FunFam; 4.10.530.10:FF:000004; Fibrinogen beta chain; 1.
DR   Gene3D; 1.20.5.50; -; 2.
DR   Gene3D; 3.90.215.10; Gamma Fibrinogen, chain A, domain 1; 1.
DR   InterPro; IPR037579; FIB_ANG-like.
DR   InterPro; IPR036056; Fibrinogen-like_C.
DR   InterPro; IPR014716; Fibrinogen_a/b/g_C_1.
DR   InterPro; IPR002181; Fibrinogen_a/b/g_C_dom.
DR   InterPro; IPR012290; Fibrinogen_a/b/g_coil_dom.
DR   InterPro; IPR020837; Fibrinogen_CS.
DR   NCBIfam; NF040941; GGGWT_bact; 1.
DR   PANTHER; PTHR47221; FIBRINOGEN ALPHA CHAIN; 1.
DR   PANTHER; PTHR47221:SF5; FIBRINOGEN C-TERMINAL DOMAIN-CONTAINING PROTEIN; 1.
DR   Pfam; PF08702; Fib_alpha; 1.
DR   Pfam; PF00147; Fibrinogen_C; 1.
DR   SMART; SM00186; FBG; 1.
DR   SMART; SM01212; Fib_alpha; 1.
DR   SUPFAM; SSF56496; Fibrinogen C-terminal domain-like; 1.
DR   SUPFAM; SSF58010; Fibrinogen coiled-coil and central regions; 1.
DR   PROSITE; PS00514; FIBRINOGEN_C_1; 1.
DR   PROSITE; PS51406; FIBRINOGEN_C_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Blood coagulation; Coiled coil;
KW   Direct protein sequencing; Disease variant; Disulfide bond; Glycoprotein;
KW   Hemostasis; Immunity; Innate immunity; Proteomics identification;
KW   Pyrrolidone carboxylic acid; Reference proteome; Secreted; Signal.
FT   SIGNAL          1..30
FT                   /evidence="ECO:0000269|PubMed:420779,
FT                   ECO:0000269|PubMed:936108, ECO:0000269|Ref.11,
FT                   ECO:0000269|Ref.13"
FT   PEPTIDE         31..44
FT                   /note="Fibrinopeptide B"
FT                   /evidence="ECO:0000269|PubMed:12665801"
FT                   /id="PRO_0000009070"
FT   CHAIN           45..491
FT                   /note="Fibrinogen beta chain"
FT                   /id="PRO_0000009071"
FT   DOMAIN          232..488
FT                   /note="Fibrinogen C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00739"
FT   REGION          44..75
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          45..47
FT                   /note="Beta-chain polymerization, binding distal domain of
FT                   another fibrin"
FT   COILED          157..222
FT                   /evidence="ECO:0000305|PubMed:10074346,
FT                   ECO:0000305|PubMed:19296670, ECO:0000305|PubMed:9628725"
FT   COMPBIAS        47..57
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            44..45
FT                   /note="Cleavage; by thrombin; to release fibrinopeptide B"
FT   SITE            152..153
FT                   /note="Cleavage; by plasmin; to break down fibrin clots"
FT   SITE            160..161
FT                   /note="Cleavage; by hementin; to prevent blood coagulation"
FT   SITE            163..164
FT                   /note="Cleavage; by plasmin; to break down fibrin clots"
FT   MOD_RES         31
FT                   /note="Pyrrolidone carboxylic acid"
FT                   /evidence="ECO:0000269|PubMed:420779"
FT   CARBOHYD        394
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:10074346,
FT                   ECO:0000269|PubMed:16263699, ECO:0000269|PubMed:16335952,
FT                   ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:9628725,
FT                   ECO:0000269|Ref.11"
FT   DISULFID        95
FT                   /note="Interchain (with C-55 in alpha chain)"
FT                   /evidence="ECO:0000269|PubMed:19296670"
FT   DISULFID        106
FT                   /note="Interchain (with C-68 in alpha chain)"
FT                   /evidence="ECO:0000269|PubMed:19296670"
FT   DISULFID        110
FT                   /note="Interchain (with C-45 in gamma chain)"
FT                   /evidence="ECO:0000305|PubMed:6575689"
FT   DISULFID        223
FT                   /note="Interchain (with C-184 in alpha chain)"
FT                   /evidence="ECO:0000269|PubMed:10074346,
FT                   ECO:0000269|PubMed:19296670, ECO:0000269|PubMed:9333233,
FT                   ECO:0000269|PubMed:9628725, ECO:0007744|PDB:1FZC"
FT   DISULFID        227
FT                   /note="Interchain (with C-161 in gamma chain)"
FT   DISULFID        231..316
FT                   /evidence="ECO:0000269|PubMed:10074346,
FT                   ECO:0000269|PubMed:19296670, ECO:0000269|PubMed:9333233,
FT                   ECO:0000269|PubMed:9628725, ECO:0007744|PDB:1FZC"
FT   DISULFID        241..270
FT                   /evidence="ECO:0000269|PubMed:10074346,
FT                   ECO:0000269|PubMed:19296670, ECO:0000269|PubMed:9333233,
FT                   ECO:0000269|PubMed:9628725, ECO:0007744|PDB:1FZC"
FT   DISULFID        424..437
FT                   /evidence="ECO:0000269|PubMed:10074346,
FT                   ECO:0000269|PubMed:19296670, ECO:0000269|PubMed:9333233,
FT                   ECO:0000269|PubMed:9628725, ECO:0007744|PDB:1FZC"
FT   VARIANT         2
FT                   /note="K -> E (in dbSNP:rs6053)"
FT                   /evidence="ECO:0000269|PubMed:10391209"
FT                   /id="VAR_014169"
FT   VARIANT         39..102
FT                   /note="Missing (in New York-1)"
FT                   /evidence="ECO:0000269|PubMed:3156856"
FT                   /id="VAR_002402"
FT   VARIANT         44
FT                   /note="R -> C (in Christchurch-2, Seattle-1 and Ijmuiden;
FT                   dbSNP:rs121909616)"
FT                   /evidence="ECO:0000269|PubMed:1565641"
FT                   /id="VAR_002403"
FT   VARIANT         45
FT                   /note="G -> R (in Ise)"
FT                   /evidence="ECO:0000269|PubMed:2018836"
FT                   /id="VAR_002404"
FT   VARIANT         74
FT                   /note="R -> C (in Nijmegen; dbSNP:rs121909619)"
FT                   /evidence="ECO:0000269|PubMed:1565641"
FT                   /id="VAR_002405"
FT   VARIANT         95
FT                   /note="C -> R (in CAFBN; hypofibrinogenemia; heterozygous;
FT                   decreased fibrinogen complex assembly; no effect on
FT                   fibrinogen complex secretion)"
FT                   /evidence="ECO:0000269|PubMed:25427968"
FT                   /id="VAR_072724"
FT   VARIANT         98
FT                   /note="A -> T (in DYSFIBRIN; fibrinogen Naples and
FT                   Milano-2; defective thrombin binding resulting in decreased
FT                   release of fibrinopeptide B; dbSNP:rs121909620)"
FT                   /evidence="ECO:0000269|PubMed:1634610"
FT                   /id="VAR_002406"
FT   VARIANT         100
FT                   /note="P -> S (in dbSNP:rs2227434)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_013091"
FT   VARIANT         170
FT                   /note="N -> H (in dbSNP:rs2227409)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_013092"
FT   VARIANT         196
FT                   /note="R -> C (in CAFBN; fibrinogen Longmont;
FT                   dbSNP:rs121909623)"
FT                   /evidence="ECO:0000269|PubMed:11468164"
FT                   /id="VAR_016908"
FT   VARIANT         202
FT                   /note="L -> Q (in CAFBN; dbSNP:rs121909624)"
FT                   /evidence="ECO:0000269|PubMed:15070683"
FT                   /id="VAR_072620"
FT   VARIANT         265
FT                   /note="P -> L (in dbSNP:rs6054)"
FT                   /evidence="ECO:0000269|PubMed:10391209, ECO:0000269|Ref.4"
FT                   /id="VAR_013093"
FT   VARIANT         365
FT                   /note="A -> T (in Pontoise-2; dbSNP:rs121909617)"
FT                   /id="VAR_002407"
FT   VARIANT         383
FT                   /note="L -> R (in CAFBN; abolishes fibrinogen secretion;
FT                   dbSNP:rs121909621)"
FT                   /evidence="ECO:0000269|PubMed:10666208"
FT                   /id="VAR_016909"
FT   VARIANT         407
FT                   /note="T -> K (in CAFBN; homozygous; heterozygous; no
FT                   effect on fibrinogen complex assembly; impaired fibrinogen
FT                   complex secretion)"
FT                   /evidence="ECO:0000269|PubMed:25427968"
FT                   /id="VAR_072725"
FT   VARIANT         430
FT                   /note="G -> D (in CAFBN; abolishes fibrinogen secretion;
FT                   dbSNP:rs121909622)"
FT                   /evidence="ECO:0000269|PubMed:10666208"
FT                   /id="VAR_016910"
FT   VARIANT         478
FT                   /note="R -> K (in Baltimore-2; dbSNP:rs4220)"
FT                   /evidence="ECO:0000269|PubMed:10391209,
FT                   ECO:0000269|PubMed:3194892, ECO:0000269|Ref.4"
FT                   /id="VAR_002408"
FT   CONFLICT        138..139
FT                   /note="SQ -> QS (in Ref. 11; AA sequence and 12; AA
FT                   sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        145..146
FT                   /note="FQ -> QF (in Ref. 10; AA sequence, 11; AA sequence
FT                   and 12; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        192
FT                   /note="P -> A (in Ref. 1; AAA52429)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        245
FT                   /note="I -> T (in Ref. 7; AAI07767)"
FT                   /evidence="ECO:0000305"
FT   TURN            100..102
FT                   /evidence="ECO:0007829|PDB:3GHG"
FT   HELIX           109..145
FT                   /evidence="ECO:0007829|PDB:3GHG"
FT   HELIX           147..167
FT                   /evidence="ECO:0007829|PDB:3GHG"
FT   HELIX           172..180
FT                   /evidence="ECO:0007829|PDB:3GHG"
FT   TURN            182..189
FT                   /evidence="ECO:0007829|PDB:1FZC"
FT   HELIX           190..222
FT                   /evidence="ECO:0007829|PDB:1FZC"
FT   STRAND          224..226
FT                   /evidence="ECO:0007829|PDB:2HOD"
FT   STRAND          233..235
FT                   /evidence="ECO:0007829|PDB:1FZC"
FT   STRAND          238..240
FT                   /evidence="ECO:0007829|PDB:1FZC"
FT   HELIX           241..246
FT                   /evidence="ECO:0007829|PDB:1FZC"
FT   STRAND          253..257
FT                   /evidence="ECO:0007829|PDB:1FZC"
FT   STRAND          261..263
FT                   /evidence="ECO:0007829|PDB:2OYH"
FT   STRAND          266..271
FT                   /evidence="ECO:0007829|PDB:1FZC"
FT   HELIX           274..276
FT                   /evidence="ECO:0007829|PDB:1FZC"
FT   STRAND          279..288
FT                   /evidence="ECO:0007829|PDB:1FZC"
FT   HELIX           296..301
FT                   /evidence="ECO:0007829|PDB:1FZC"
FT   STRAND          302..304
FT                   /evidence="ECO:0007829|PDB:1FZF"
FT   STRAND          306..308
FT                   /evidence="ECO:0007829|PDB:1FZC"
FT   STRAND          311..315
FT                   /evidence="ECO:0007829|PDB:2H43"
FT   STRAND          321..323
FT                   /evidence="ECO:0007829|PDB:1FZC"
FT   HELIX           326..334
FT                   /evidence="ECO:0007829|PDB:1FZC"
FT   STRAND          335..337
FT                   /evidence="ECO:0007829|PDB:2HOD"
FT   STRAND          339..345
FT                   /evidence="ECO:0007829|PDB:1FZC"
FT   STRAND          347..349
FT                   /evidence="ECO:0007829|PDB:1FZA"
FT   STRAND          351..361
FT                   /evidence="ECO:0007829|PDB:1FZC"
FT   HELIX           364..366
FT                   /evidence="ECO:0007829|PDB:1FZC"
FT   STRAND          370..379
FT                   /evidence="ECO:0007829|PDB:1FZC"
FT   HELIX           382..385
FT                   /evidence="ECO:0007829|PDB:1FZC"
FT   STRAND          388..390
FT                   /evidence="ECO:0007829|PDB:2HPC"
FT   HELIX           392..396
FT                   /evidence="ECO:0007829|PDB:1FZC"
FT   STRAND          404..407
FT                   /evidence="ECO:0007829|PDB:2HOD"
FT   STRAND          408..410
FT                   /evidence="ECO:0007829|PDB:1FZB"
FT   HELIX           420..422
FT                   /evidence="ECO:0007829|PDB:2OYI"
FT   TURN            424..428
FT                   /evidence="ECO:0007829|PDB:1FZC"
FT   STRAND          435..437
FT                   /evidence="ECO:0007829|PDB:1FZC"
FT   STRAND          439..441
FT                   /evidence="ECO:0007829|PDB:3E1I"
FT   STRAND          448..451
FT                   /evidence="ECO:0007829|PDB:3BVH"
FT   TURN            454..456
FT                   /evidence="ECO:0007829|PDB:1FZC"
FT   STRAND          457..461
FT                   /evidence="ECO:0007829|PDB:3HUS"
FT   STRAND          464..467
FT                   /evidence="ECO:0007829|PDB:3E1I"
FT   HELIX           468..471
FT                   /evidence="ECO:0007829|PDB:1FZC"
FT   STRAND          473..475
FT                   /evidence="ECO:0007829|PDB:2OYH"
FT   STRAND          478..485
FT                   /evidence="ECO:0007829|PDB:1FZC"
SQ   SEQUENCE   491 AA;  55928 MW;  B92FFB9976AB53C5 CRC64;
     MKRMVSWSFH KLKTMKHLLL LLLCVFLVKS QGVNDNEEGF FSARGHRPLD KKREEAPSLR
     PAPPPISGGG YRARPAKAAA TQKKVERKAP DAGGCLHADP DLGVLCPTGC QLQEALLQQE
     RPIRNSVDEL NNNVEAVSQT SSSSFQYMYL LKDLWQKRQK QVKDNENVVN EYSSELEKHQ
     LYIDETVNSN IPTNLRVLRS ILENLRSKIQ KLESDVSAQM EYCRTPCTVS CNIPVVSGKE
     CEEIIRKGGE TSEMYLIQPD SSVKPYRVYC DMNTENGGWT VIQNRQDGSV DFGRKWDPYK
     QGFGNVATNT DGKNYCGLPG EYWLGNDKIS QLTRMGPTEL LIEMEDWKGD KVKAHYGGFT
     VQNEANKYQI SVNKYRGTAG NALMDGASQL MGENRTMTIH NGMFFSTYDR DNDGWLTSDP
     RKQCSKEDGG GWWYNRCHAA NPNGRYYWGG QYTWDMAKHG TDDGVVWMNW KGSWYSMRKM
     SMKIRPFFPQ Q
//
